GlassScriptPhysician profile
Darush Rahmani
NPI 1598714495
$1,039.82
in general payments reported to CMS, 2019-2025
12 companies · $20.28 in 2025
The $20.28 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $209 · 2021: $587 · 2022: $53.81 · 2023: $58.51 · 2025: $20.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $78.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $78.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $325.05 | 2019-2022 | |
| Abbvie INC. | $240.73 | 2020-2023 | |
| Welch Allyn | $185.58 | 2021 | |
| Janssen Biotech, INC. | $99.31 | 2020-2022 | |
| Amgen INC. | $86.93 | 2020-2025 | Tavneos |
| Glaxosmithkline, LLC. | $39.24 | 2021-2022 | |
| Radius Health, INC. | $24.47 | 2019 | |
| Pfizer INC. | $14.27 | 2019 | |
| Genentech USA, INC. | $12.70 | 2019 | |
| Avion Pharmaceuticals | $11.54 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darush Rahmani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.